Read about Essure, Diabetes and more in the November FDA Women's Health eUpdate

["FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Read about Essure, Diabetes and more in the November FDA Women's Health eUpdate

November 2015
www.fda.gov/womens

Message from the Director

During this time of year, I want to take time to say thank you to all of the organizations and individuals who help to share FDA’s health and safety information with the women across the country. The Office of Women’s Health sends out updates, email alerts and social media messages to make sure that women have the information they need to make informed choices about the medicines, foods, and other FDA-regulated products they use every day. We rely on you to help amplify and disseminate these messages, and you have consistently used your voices and platforms to help. For this we are grateful.

Marsha Henderson - Assistant Commissioner for Women’s Health

FDA Women's health highlights

Update on FDA's Evaluation of Essure

FDA issued an update on the status of the Agency’s evaluation of adverse events that have been reported for the Essure System, a form of permanent birth control (female sterilization). FDA is reviewing information from the panel meeting, the public docket, as well as additional medical literature and adverse event reports which have been published or received since the panel meeting. This is a high priority issue for the Agency. FDA anticipates communicating our actions publically at the end of February 2016. Read the Essure Update Learn more about Essure

Resources for Women with Diabetes

FDA’s Women and Diabetes webpage highlights videos, easy-to-read publications, and other resources that can be used to educate women about the safe use of FDA-approved medicines and medical devices for diabetes management. The webpage also features links to food safety tips and information on diabetes during pregnancy. Visit and Share the Women and Diabetes webpage

Extras

Blood-thinning drug does not change risk of death

A FDA review has determined that long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. FDA’s evaluation of the Dual Antiplatelet Therapy (DAPT)1 trial and several other clinical trials also does not suggest that clopidogrel increases the risk of cancer or death from cancer.

Patients should not stop taking clopidogrel or other antiplatelet medicines because doing so may result in an increased risk of heart attacks and blood clots. Talk with your health care professional if you have any questions or concerns about clopidogrel. Health care professionals should consider the benefits and risks of available antiplatelet medicines before starting treatment.

View the Drug Safety Communication

FDA Meetings

Psychopharmacologic Drugs Advisory Committee

December 1, 2015 - FDA White Oak Campus, Silver Spring, MD

 

FDA Conference - Clinical Trials: Assessing Safety and Efficacy for a Diverse Population

December 2, 2015 - FDA White Oak Campus, Silver Spring, MD

 

Please share this update with your network, members, constituents, and community

FDA Office of Women's Health
10903 New Hampshire Avenue
WO32 - Room 2333
Silver Spring, MD 20993*0002
301-796-9440

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420